Loading...
Loading...
Embla Medical HF/ADR
Embla Medical HF/ADR. Spoken Alpha tracks OSSUY's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks OSSUY's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for OSSUY.
curl https://api.spokenalpha.com/v1/companies/OSSUY| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.93 | $3.32 | +18.5% | -7.4% | -5.3% |
| Q4 FY2026 | $3.99 | $3.23 | +23.6% | +2.9% | +2.3% |
| Q3 FY2026 | $4.20 | $3.42 | +22.7% | +0.6% | -1.6% |
| Q2 FY2026 | $4.22 | $3.46 | +22.0% | +3.8% | +6.8% |
| Q1 FY2025 | $4.05 | $3.27 | +24.0% | -2.2% | +0.3% |
| Q4 FY2025 | $3.97 | $3.35 | +18.4% | -5.4% | -3.2% |
| Q3 FY2025 | $3.81 | $3.33 | +14.4% | 0.0% | -1.8% |
| Q2 FY2025 | $4.06 | $3.47 | +17.1% | -1.8% | -0.7% |
| Q1 FY2024 | $4.37 | $3.55 | +23.0% | +0.7% | +3.6% |
| Q4 FY2024 | $3.93 | $3.36 | +17.1% | -6.9% | -5.8% |